Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
Definium Therapeutics NASDAQ: DFTX Chief Medical Officer Dan Karlin said the company's recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open-label portions of the studies still underway.
Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study
Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivotal-study results previously reported in GAD and major depressive disorder.
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
Definium Therapeutics' DT120 Meets Phase III Goals in GAD Study
Definium Therapeutics NASDAQ: DFTX reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durable improvements in anxiety symptoms through 12 weeks.
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder Transcript
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call Prepared Remarks Transcript
Definium Therapeutics Q2 Earnings Call Highlights
Definium Therapeutics NASDAQ: DFTX said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following positive Phase III results in major depressive disorder reported in June.
Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.9% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical company reported positive topline results from its Phase 3 Emerge study evaluating DT120, an orally disintegrating formulation of lysergide (LSD), in adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled trial met its primary endpoint and all key secondary efficacy endpoints.
